October 19, 2005 13:51 ET

Nymox Signs New Marketing and Distribution Deal for NicAlert™ Test in Spain

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Oct 19, 2005) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that it has entered into a new distribution agreement with RAL Tecnica para el laboratoria S. A. (RAL) for the marketing and sales of Nymox's NicAlert™ product in Spain. RAL Tecnica is a leading Spanish diagnostic and clinical chemistry marketing company based in Barcelona, with an extensive sales and distribution network throughout Spain.

"We are delighted to be working with RAL to make the NicAlert™ test available to physicians, researchers, and laboratories in Spain," said Brian Doyle, Nymox's Senior Manager for Worldwide Sales and Marketing. "We continue to make inroads in the European market with this unique product."

Nymox's NicAlert™ product provides a proven, easy-to-use, on-site means of determining an individual's use of or exposure to tobacco products. The product gives a visual read-out of the level of tobacco use or exposure within minutes and requires no instruments to use. NicAlert™ has received U.S. FDA clearance for medical use for determining an individual's exposure to tobacco products.

NicAlert™ uses powerful, one-step patented technology to measure the level of cotinine, a metabolite of nicotine, in urine. Cotinine is widely accepted and commonly used in medical research and public health studies to determine the extent of tobacco product use or exposure. NicAlert™ testing can be performed almost anywhere, including at home, the workplace or school.

Nymox also offers TobacAlert™, which is for non-medical uses and can detect second-hand smoke exposure. TobacAlert™ is available at approximately 5,400 CVS/pharmacy® stores across the U.S. as well as online at www.cvs.com. More information about TobacAlert™ is available at www.tobacalert.com.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX